Hospital
Independent Healthcare Management, INC.
Independent Healthcare Management, INC. was paid $12.39M by Medicaid between Jan 2018 and Dec 2024, across 131 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoINDEPENDENT HEALTHCARE MANAGEMENT, INC.
FOREST, MS 39074
FOREST, MS 39074
33aNPI1306909734assigned 12/18/2006
33bProvider typeCritical Access Hospital
28Total paid$12.39M
24GClaims283,682
24DCodes billed131
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#2 of 32
Median peer was paid$3.94M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LEE, JOHN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,441 | $1.80M | |
| 2019 | 41,792 | $2.17M | |
| 2020 | 31,205 | $1.47M | |
| 2021 | 43,568 | $1.99M | |
| 2022 | 50,588 | $1.87M | |
| 2023 | 45,492 | $1.83M | |
| 2024incomplete | 33,596 | $1.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 10,080 | 8,041 | $2.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 8,475 | 7,293 | $1.63M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 10% | 35,914 | 2,078 | $1.28M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 10.0% | 4,570 | 4,143 | $1.24M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 7,397 | 6,336 | $741K |
| G0378 | Hospital observation service, per hour | 5.1% | 1,545 | 1,167 | $631K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 3.1% | 6,641 | 1,312 | $384K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 3,901 | 3,294 | $329K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 2,293 | 1,237 | $266K |
| 87507 | 2.0% | 685 | 624 | $244K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 5,737 | 4,200 | $187K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 933 | 695 | $166K |
119 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 3,123 | $159K |
| 80053 | Comprehensive metabolic panel | 1.3% | 17,481 | $159K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 21,172 | $156K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 2,543 | $152K |
| 87486 | 1.2% | 5,302 | $149K | |
| 87581 | 1.2% | 5,300 | $149K | |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 4,730 | $144K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.1% | 6,979 | $142K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,439 | $116K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,287 | $110K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,160 | $103K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,952 | $83K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 887 | $82K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 1,111 | $78K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,581 | $68K |
| 80061 | Lipid panel | <1% | 5,645 | $64K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,745 | $55K |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 5,748 | $51K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,661 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,659 | $45K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,368 | $44K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,143 | $43K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,844 | $41K |
| 83880 | <1% | 1,731 | $40K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 334 | $34K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,520 | $34K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,141 | $32K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 279 | $26K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 606 | $25K |
| 84484 | <1% | 3,399 | $24K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 242 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,441 | $22K |
| 83735 | <1% | 4,544 | $21K | |
| 81001 | <1% | 7,453 | $20K | |
| 73562 | <1% | 467 | $19K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 44 | $19K |
| 84703 | <1% | 2,791 | $19K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 238 | $17K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 64 | $17K |
| 80305 | <1% | 1,889 | $16K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 257 | $15K |
| 73630 | <1% | 369 | $15K | |
| 82607 | <1% | 1,248 | $13K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 610 | $13K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 47 | $12K |
| 73030 | <1% | 324 | $12K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 512 | $11K |
| 83690 | <1% | 2,089 | $10K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 89 | $9K |
| 73610 | <1% | 183 | $9K | |
| 82746 | <1% | 778 | $9K | |
| 83874 | <1% | 955 | $8K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 57 | $8K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 180 | $8K |
| 82553 | <1% | 1,008 | $8K | |
| 83605 | <1% | 1,404 | $8K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 195 | $7K |
| 82728 | <1% | 662 | $6K | |
| 73130 | <1% | 116 | $6K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 471 | $6K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 75 | $4K |
| A9270 | Non-covered item or service | <1% | 1,346 | $4K |
| 72110 | <1% | 79 | $4K | |
| 87040 | <1% | 620 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 96 | $3K |
| 86140 | <1% | 898 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,288 | $3K |
| 83550 | <1% | 518 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 15 | $3K |
| 83540 | <1% | 533 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 14 | $3K |
| 96376 | <1% | 1,136 | $2K | |
| 87481 | <1% | 126 | $2K | |
| 87070 | <1% | 171 | $2K | |
| 82150 | <1% | 325 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 44 | $2K |
| 87625 | <1% | 99 | $2K | |
| 73110 | <1% | 45 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 86 | $2K |
| 87561 | <1% | 91 | $2K | |
| 86756 | <1% | 115 | $2K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 188 | $2K |
| 80076 | <1% | 299 | $1K | |
| 82043 | <1% | 213 | $1K | |
| 85610 | <1% | 495 | $1K | |
| 73502 | <1% | 40 | $1K | |
| 74019 | <1% | 15 | $1K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 22 | $1K |
| 85379 | <1% | 190 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 456 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 667 | $1K |
| 87529 | <1% | 50 | $1K | |
| 87496 | <1% | 50 | $1K | |
| 87532 | <1% | 50 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 883 | $1K |
| 72100 | <1% | 17 | $815.99 | |
| 94664 | <1% | 237 | $770.03 | |
| 87653 | <1% | 33 | $704.37 | |
| 87511 | <1% | 35 | $600.02 | |
| 82565 | <1% | 168 | $548.28 | |
| 85651 | <1% | 176 | $512.59 | |
| 82570 | <1% | 123 | $436.57 | |
| 85730 | <1% | 162 | $428.51 | |
| 87640 | <1% | 20 | $420.15 | |
| 84439 | <1% | 31 | $255.21 | |
| J2704 | Injection, propofol, 10 mg | <1% | 882 | $254.03 |
| 87807 | <1% | 14 | $202.76 | |
| 82550 | <1% | 17 | $118.56 | |
| 82962 | <1% | 67 | $103.98 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 48 | $30.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 279 | $8.32 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 85 | $3.60 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 22 | $3.60 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 30 | $0.00 |
| 94761 | 0% | 58 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 21 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 14 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEE, JOHN (CHAIRMAN OF THE BOARD)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.